Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Risk Tool Shows Promise for Predicting Adverse Opioid-Related Outcomes in Cancer Survivors

November 25, 2019
By Hannah Slater
Article

Predictive models demonstrated the ability to anticipate adverse opioid-related outcomes among cancer survivors.

A study released by the National Cancer Institute demonstrated the potential for a risk tool to forecast adverse opioid-related outcomes among cancer survivors.

Personalized risk stratification approaches could guide management when prescribing opioids in patients with cancer, with further validation.

In this cohort of 106,732 Veteran cancer survivors, the overall incidence of persistent post-treatment opioid use was 8.3% (95% CI, 8.1-8.4) which varied by cancer type. The rates of persistent opioid use after treatment varied substantially by a patient’s history of opioid use prior to their cancer diagnosis.

Predictive models showed a high level of discrimination when identifying individuals at risk of adverse opioid-related outcomes including persistent opioid use (area under curve [AUC] =  0.85), future diagnoses of opioid abuse of dependence (AUC = 0.87), and admission for opioid abuse or toxicity (AUC = 0.78).

Researchers developed an online risk tool for these predictive models to assist with clinical implementation (www.CancerOpioidRisk.org).

“Similar to cancer stage informing the management of anti-neoplastic therapy, an accurate prediction of future opioid-related morbidity can be used to personalize pain management and mitigate adverse outcomes,” the researchers wrote.

Current guidelines suggest strategies including establishing a signed treatment agreement, periodic urine drug testing, patient and caregiver education, referrals to palliative medicine or a pain specialist, avoidance of high-risk formulations, and minimizing total daily dose for patients at increased risk of adverse opioid-related outcomes.

Cancers with more intensive, multi-modal therapies had the highest adjusted risk for persistent opioid use including esophagus, pancreas, liver, head and neck, and lung cancer. Prior opioid use was highly associated with future chronic use. The results also supported prior research indicating increased risk for opioid use among younger patients, the unemployed, current or former smokers, and those with a prior diagnosis of depression or drug abuse.

Other factors associated with opioid risk identified in this study such as race, median income, non-abusive alcohol use, comorbidity, body mass index, and cancer type have not been previously reported. Researchers also found no association between gender and persistent opioid use, which differs from other studies, though there was a skewed gender distribution due to the study population coming from within the VA healthcare system.

“Despite these limitations, this current study represents one of the largest comprehensive evaluations of persistent opioid use and abuse in cancer survivors, and the first to construct a predictive model in oncology patients,” the researchers wrote.

According to a study published in September of 2018 that looked at the opioid epidemic over the past 10 years, death from opioids as the primary cause noted on death certificates are 10 times less likely to occur in patients with cancer versus the general population.2

Validation in a non-VA cohort of cancer patients is required to help understand generalizability of the findings and determine the predictive ability for the general population.

References:
1. Vitzthum LK, Riviere P, Sheridan P, et al. Predicting Persistent Opioid Use, Abuse and Toxicity Among Cancer Survivors. International Journal of Radiation Oncology. September 2019;105(1);S71. doi:10.1016/j.ijrobp.2019.06.524.
2. Chino FL, Kamal A, Chino JP. Opioid-associated deaths in patients with cancer: A population study of the opioid epidemic over the past 10 years. Presented at: 2018 ASCO Quality care Symposium; September 28-29, 2018; Phoenix, AZ. Abstract 230.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Tim Cortese
July 25th 2025
Article

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Tim Cortese
July 20th 2025
Article

Short-course radiotherapy combined with sintilimab plus oxaliplatin-capecitabine yielded a pCR rate of 59.2% vs 32.7% with the control arm in locally advanced rectal cancer.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.

Transarterial Chemoembolization Regimen Shows PFS Improvement in HCC

Roman Fabbricatore
July 16th 2025
Article

Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.


Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

Kristi Rosa
July 14th 2025
Article

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Related Content

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Tim Cortese
July 25th 2025
Article

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Tim Cortese
July 20th 2025
Article

Short-course radiotherapy combined with sintilimab plus oxaliplatin-capecitabine yielded a pCR rate of 59.2% vs 32.7% with the control arm in locally advanced rectal cancer.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.

Transarterial Chemoembolization Regimen Shows PFS Improvement in HCC

Roman Fabbricatore
July 16th 2025
Article

Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.


Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

Kristi Rosa
July 14th 2025
Article

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.